Skip to main content
. 2021 Feb 3;11:624758. doi: 10.3389/fimmu.2020.624758

Figure 1.

Figure 1

Concentration of LAMP-2-ANCA in pediatric chronic small-to-medium vessel vasculitis patients. (A) LAMP-2-ANCA concentration (y-axis; ng/mL) in serum of individuals with early-onset vasculitis that are known to be positive (n = 5) and negative (n = 1) for LAMP-2-ANCA (squares) (14), children with vasculitis (n = 51, circles), and children with systemic autoinflammatory disease (n = 5, triangles). (B) LAMP-2-ANCA concentration (y-axis; ng/mL) in pediatric patients grouped (x-axis) based on positivity for MPO-ANCA (n = 19), PR3-ANCA (n = 23), or neither MPO- or PR3-ANCA (ANCA-, n = 7), and (C, D) LAMP-2-ANCA concentration (y-axis; ng/mL) plotted against (C) MPO-ANCA (x-axis; U/L) (n =19) and (D) PR3-ANCA (x-axis; U/L) (n = 23). Bars show median. Horizontal line divided low (<1,000 ng/mL) and moderate-high positive LAMP-2-ANCA (>1,000 ng/mL). Open symbols on the x-axis denote samples below the lower limit of detection of the assay (n = 4 patients with vasculitis, and n = 1 patient with autoinflammatory disease).